More from U.S. Equity
In late August/early September the major indices were making medium-term tops.
Obstacles that lie ahead, but this market never seems to embrace a negative narrative for long.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
The greedy are, at last, getting blown out, and the prudent being vindicated. I see three buckets of stocks that intrigue me now.